Interferon alpha kinoid (Neovacs) Due Diligence Report 2026

This Interferon alpha kinoid (Neovacs) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Interferon alpha kinoid (Neovacs) can convert its Interferons profile and IFN α x Type I IFN Receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Interferon alpha kinoid (Neovacs) (query alias: Interferon alpha kinoid (Neovacs))
Modality / target	Interferons; IFN α x Type I IFN Receptor; IFNA inhibitors, IFNAR agonists
Highest global status	Phase 2
Originator	Neovacs SA
Active developers	Neovacs SA, Chong Kun Dang Pharmaceutical Corp.

The MCP disease footprint includes Systemic Lupus Erythematosus, Lupus Erythematosus. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT02980198	Phase 2	Withdrawn	0	Primary endpoint not disclosed in English source
PER-052-15	Phase 2	Complete	12	Primary endpoint not disclosed in English source
NCT02665364	Phase 2	Terminated	185	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus

Phase 2; n=185; evaluation: Not stated in English source. Reported fields: Percent Change From Baseline in IFN Gene Signature at W36(Mean) = -0.44 %

IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study

Phase 2; n=185; evaluation: Positive. Reported fields: BICLA(36-week) = 41 % ; BICLA(36-week) = 34 %

IFNα kinoid is a promising vaccine against type 1 diabetes targeting IFNα in the NOD mouse model

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: T1D onset delay = 10 Week ; Insulitis = 20 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Interferon alpha kinoid (Neovacs) addresses Systemic Lupus Erythematosus, Lupus Erythematosus. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Interferons—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 3 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-10-11	Neovacs Announces The Continuation Of The Development Of Its IFNALPHA KINOID In South Korea With Its Partner Chong Kun Dang (Ckd) Pharmaceuticals	Phase 2	US$5.5M stated total
2017-07-05	Neovacs and Centurion sign licence agreement for lupus treatment IFNalpha Kinoid in Turkey	Phase 2	US$6.5M stated total
2017-02-21	Neovacs and BioSense Sign Option Agreement Worth Up to €65 Million Plus Royalties for Chinese Development and Commercial Rights to IFNα Kinoid for Lupus and Dermatomyositis	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO